Pharming Group NV (PHAR) - Net Assets
Based on the latest financial reports, Pharming Group NV (PHAR) has net assets worth $268.96 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($489.37 Million) and total liabilities ($220.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Pharming Group NV to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $268.96 Million |
| % of Total Assets | 54.96% |
| Annual Growth Rate | 11.05% |
| 5-Year Change | 43.59% |
| 10-Year Change | 858.97% |
| Growth Volatility | 115.08 |
Pharming Group NV - Net Assets Trend (2005–2025)
This chart illustrates how Pharming Group NV's net assets have evolved over time, based on quarterly financial data. See Pharming Group NV defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Pharming Group NV (2005–2025)
The table below shows the annual net assets of Pharming Group NV from 2005 to 2025. For live valuation and market cap data, see market cap of Pharming Group NV.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $277.02 Million | +25.31% |
| 2024-12-31 | $221.06 Million | +1.04% |
| 2023-12-31 | $218.78 Million | +6.91% |
| 2022-12-31 | $204.64 Million | +6.08% |
| 2021-12-31 | $192.92 Million | +28.47% |
| 2020-12-31 | $150.16 Million | +27.92% |
| 2019-12-31 | $117.39 Million | +66.18% |
| 2018-12-31 | $70.64 Million | +213.15% |
| 2017-12-31 | $22.56 Million | -21.91% |
| 2016-12-31 | $28.89 Million | +10.83% |
| 2015-12-31 | $26.06 Million | -28.18% |
| 2014-12-31 | $36.29 Million | +424.55% |
| 2013-12-31 | $6.92 Million | +168.36% |
| 2012-12-31 | $-10.12 Million | -557.23% |
| 2011-12-31 | $-1.54 Million | -111.46% |
| 2010-12-31 | $13.43 Million | -29.58% |
| 2009-12-31 | $19.07 Million | +9.33% |
| 2008-12-31 | $17.45 Million | -65.51% |
| 2007-12-31 | $50.58 Million | -23.11% |
| 2006-12-31 | $65.78 Million | +93.26% |
| 2005-12-31 | $34.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pharming Group NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8200737204.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.01 Million | 2.89% |
| Other Components | $541.91 Million | 195.62% |
| Total Equity | $277.02 Million | 100.00% |
Pharming Group NV Competitors by Market Cap
The table below lists competitors of Pharming Group NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yunnan QuakeSafe Seismic Isolation Technologies Co Ltd Class A
SHE:300767
|
$893.50 Million |
|
Tortoise Energy Infrastructure Closed Fund
NYSE:TYG
|
$893.57 Million |
|
Quidel Corporation
NASDAQ:QDEL
|
$893.91 Million |
|
Zhejiang Founder Motor Co Ltd
SHE:002196
|
$893.96 Million |
|
Formosa Taffeta Co Ltd
TW:1434
|
$893.17 Million |
|
Kunshan Guoli Electronic Technology Co Ltd
SHG:688103
|
$893.07 Million |
|
Neuca S.A.
WAR:NEU
|
$892.89 Million |
|
Hangzhou Anysoft Information Technology Co Ltd
SHE:300571
|
$892.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharming Group NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 221,061,000 to 277,017,081, a change of 55,956,081 (25.3%).
- Net income of 2,858,943 contributed positively to equity growth.
- Other comprehensive income increased equity by 209,000.
- Other factors increased equity by 52,888,138.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.86 Million | +1.03% |
| Other Comprehensive Income | $209.00K | +0.08% |
| Other Changes | $52.89 Million | +19.09% |
| Total Change | $- | 25.31% |
Book Value vs Market Value Analysis
This analysis compares Pharming Group NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.26x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.37x to 3.26x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $34.13 | $12.65 | x |
| 2006-12-31 | $60.63 | $12.65 | x |
| 2007-12-31 | $44.18 | $12.65 | x |
| 2008-12-31 | $15.11 | $12.65 | x |
| 2009-12-31 | $13.04 | $12.65 | x |
| 2010-12-31 | $4.31 | $12.65 | x |
| 2011-12-31 | $-0.26 | $12.65 | x |
| 2012-12-31 | $-1.10 | $12.65 | x |
| 2013-12-31 | $0.15 | $12.65 | x |
| 2014-12-31 | $0.73 | $12.65 | x |
| 2015-12-31 | $0.51 | $12.65 | x |
| 2016-12-31 | $0.56 | $12.65 | x |
| 2017-12-31 | $0.36 | $12.65 | x |
| 2018-12-31 | $0.86 | $12.65 | x |
| 2019-12-31 | $1.39 | $12.65 | x |
| 2020-12-31 | $1.85 | $12.65 | x |
| 2021-12-31 | $2.20 | $12.65 | x |
| 2022-12-31 | $2.43 | $12.65 | x |
| 2023-12-31 | $3.33 | $12.65 | x |
| 2024-12-31 | $3.21 | $12.65 | x |
| 2025-12-31 | $3.88 | $12.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharming Group NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.76%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 1.80x
- Recent ROE (1.03%) is above the historical average (-91.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -62.14% | -4409.64% | 0.01x | 1.20x | $-24.56 Million |
| 2006 | -37.11% | -12582.36% | 0.00x | 1.59x | $-30.99 Million |
| 2007 | -102.65% | -5161.16% | 0.01x | 3.30x | $-56.98 Million |
| 2008 | -209.09% | -3946.54% | 0.01x | 5.35x | $-38.22 Million |
| 2009 | -240.82% | -2925.18% | 0.02x | 4.20x | $-47.84 Million |
| 2010 | -518.84% | -9837.18% | 0.02x | 3.43x | $-76.41 Million |
| 2011 | 0.00% | -570.32% | 0.12x | 0.00x | $-22.01 Million |
| 2012 | 0.00% | -227.01% | 0.63x | 0.00x | $-30.85 Million |
| 2013 | -300.60% | -220.05% | 0.22x | 6.27x | $-21.49 Million |
| 2014 | -19.32% | -27.22% | 0.38x | 1.87x | $-10.64 Million |
| 2015 | -41.77% | -91.96% | 0.19x | 2.42x | $-13.49 Million |
| 2016 | -63.84% | -110.48% | 0.13x | 4.62x | $-21.33 Million |
| 2017 | -425.26% | -89.22% | 0.54x | 8.84x | $-98.18 Million |
| 2018 | 40.47% | 18.50% | 0.63x | 3.47x | $21.53 Million |
| 2019 | 34.55% | 21.41% | 0.74x | 2.18x | $28.82 Million |
| 2020 | 25.14% | 17.79% | 0.62x | 2.28x | $22.73 Million |
| 2021 | 8.29% | 8.04% | 0.50x | 2.06x | $-3.30 Million |
| 2022 | 6.68% | 6.65% | 0.48x | 2.08x | $-6.79 Million |
| 2023 | -4.82% | -4.30% | 0.53x | 2.12x | $-32.43 Million |
| 2024 | -5.36% | -3.98% | 0.74x | 1.81x | $-33.95 Million |
| 2025 | 1.03% | 0.76% | 0.75x | 1.80x | $-24.84 Million |
Industry Comparison
This section compares Pharming Group NV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharming Group NV (PHAR) | $268.96 Million | -62.14% | 0.82x | $893.41 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more